Compare Liquidia Corporation Common Stock (LQDA) vs Oruka Therapeutics Inc. Common Stock (ORKA) Price & Performance

Liquidia Corporation Common StockTrade

Oruka Therapeutics Inc. Common StockTrade

Price performance (Past 24H)

Key statistics

Liquidia Corporation Common Stock vs Oruka Therapeutics Inc. Common Stock — how do they compare? Liquidia Corporation Common Stock trades at $33.69 (market cap $2.40B), while Oruka Therapeutics Inc. Common Stock trades at $75.2 (market cap $5.18B). The key difference: Oruka Therapeutics Inc. Common Stock is far larger — about 2.2× Liquidia Corporation Common Stock's market cap, and Oruka Therapeutics Inc. Common Stock is trading nearer its 52-week high, Liquidia Corporation Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Liquidia Corporation Common Stock for 0 Days and Oruka Therapeutics Inc. Common Stock for 0 Days on average.

	LQDA	ORKA
Market Cap	$2.40B	$5.18B
Volume	2,857,547	490,798
Sector	Health	Health
52-Week High	$91.03	$113.08
52-Week Low	$22.02	$26.19
Typical Hold Time	0 Days	0 Days
Enterprise Value	$2.30B	$4.31B

View details →View details →

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

LQDA

62% Buy38% Sell

Avg holding period · 0 Days

ORKA

100% Buy0% Sell

Avg holding period · 0 Days

Top news

Latest headlines on both assets

LQDA

Bending Spoons jumps 41% as Berkshire Hathaway boosts stake; Antelope Enterprise and others also surge.Andrew Wynn · 8 hours agoBullish Liquidia shares jump 25% after settling patent lawsuits with United TherapeuticsProactive Investors · 16 hours agoBullish Liquidia settles patent dispute with United Therapeutics, stock jumps 42% despite $380M payout.24/7 Wall Street · 18 hours agoBullish View details →

ORKA

View details →

About Liquidia Corporation Common Stock

Liquidia Corporation is a biopharmaceutical company that develops therapies for rare cardiopulmonary diseases, including YUTREPIA, an inhaled treprostinil powder for pulmonary hypertension built on its PRINT technology.

About Oruka Therapeutics Inc. Common Stock

Oruka Therapeutics, Inc. is a clinical-stage biotechnology company developing extended half-life monoclonal antibodies for plaque psoriasis, psoriatic arthritis, and related dermatologic conditions, with lead candidates ORKA-001 and ORKA-002 in clinical trials.